This page shows the latest China pharma market news and features for those working in and with pharma, biotech and healthcare.
of non-small cell lung cancer (NSCLC) in China in less than a year. ... The increasing size and growth of China’s pharma market has made it a significant target for many big Western pharma companies, but the approval of new cancer immunotherapies has
As the world’s second-largest healthcare market after the US, China has been a target for many big pharma companies, and AstraZeneca is already among the multinational drug industry’s ... The announcement of the new investment fund is just one way
China is an important market for the orally-active drug because it has far more CKD patients than the US – some estimates suggest five times as many. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while Astellas
Chi-Med has achieved a major milestone for itself and China’s fast-developing pharma market, announcing today the launch of cancer treatment Elunate (fruquintinib) in the country. ... However companies like Chi-Med can rely on the sheer scale of
China’s pharma market was worth $140bn last year, according to BMI Research, and is predicted to rise 15% to almost $170bn this year thanks to its large and expanding population, ... The size of the market has made it a big target for many big pharma
AstraZeneca has signed another deal to help it unlock the Chinese pharma market, setting up a new joint venture company to bring its drugs to market there more quickly. ... Other investments by AZ in China - now the second-largest pharma market in the
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
and a series of sweeping reforms is now opening China’s pharma market to rapid modernisation. ... China is already the world’s second biggest market for pharma, worth $123bn in revenues last year, according to LEK Consulting.
Clearly China is a major market for everything. But the number of diabetes patients is growing strongly there. ... Clearly China is a major market for everything, but we see an opportunity there for our diabetes portfolio.
Pope Woodhead highlights the key steps to accessing the high-value therapeutics market in China. ... long-term strategy to access the market, unlocking regional opportunities for reimbursement in China is viable.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
and learn how to conduct effective market research in China - including methodologies and avoiding pitfalls. ... We offer workshops on how to conduct effective market research in the 4 BRIC markets, held at your offices at a date and time to suit you.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...